Company Growth (employees)
Juno Therapeutics was founded in 2013 and is headquartered in Seattle, US
Key People at Juno Therapeutics
Hans Bishop
CEO
Juno Therapeutics Office Locations
Juno Therapeutics has offices in Seattle, Washington, Bothell, Waltham and in 2 other locations
Seattle, US (HQ)
300 307 Westlake Ave N
Juno Therapeutics Data and Metrics
Juno Therapeutics Financial Metrics
Juno Therapeutics's revenue was reported to be $19.3 m in Q1, 2017
USD
Revenue (Q1, 2017) | 19.3 m |
Net income (Q1, 2017) | (82.2 m) |
EBIT (Q1, 2017) | (84.3 m) |
Market capitalization (22-Aug-2017) | 2.9 b |
Cash (31-Mar-2017) | 205.7 m |
Juno Therapeutics's current market capitalization is $2.9 b.
- Source: SEC Filings
| USD | FY, 2015 | FY, 2016 |
|---|---|---|
Revenue | 18.2 m | 79.4 m |
Revenue growth, % | 336% | |
R&D expense | 46.2 m | 264.3 m |
General and administrative expense | 4.2 m | 70.7 m |
Operating expense total | 50.5 m | 335 m |
EBIT | (51.7 m) | (255.6 m) |
EBIT margin, % | (284%) | (322%) |
Pre tax profit | (51.8 m) | (256.2 m) |
Income tax expense | 2.8 m | 10.7 m |
Net Income | (51.8 m) | (245.6 m) |
| USD | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|
Revenue | 12.5 m | 1.6 m | 9.8 m | 27.6 m | 20.8 m | 19.3 m | |
R&D expense | 57.8 m | 60.2 m | 11.5 m | 73.7 m | 72.3 m | 60.9 m | 82.9 m |
General and administrative expense | 6.7 m | 14.9 m | 13.6 m | 16 m | 16.8 m | 18.4 m | 20.7 m |
Operating expense total | 64.5 m | 75.1 m | 25.1 m | 89.7 m | 89.1 m | 79.3 m | 103.7 m |
EBIT | (65.2 m) | (68 m) | (23.5 m) | (79.9 m) | (61.5 m) | (58.5 m) | (84.3 m) |
EBIT margin, % | (545%) | (1469%) | (817%) | (223%) | (281%) | (436%) | |
Pre tax profit | (67.6 m) | (23.2 m) | (78.5 m) | (66 m) | (57.5 m) | (83.5 m) | |
Income tax expense | (63 k) | 594 k | 1.3 m | ||||
Net Income | (65 m) | (66 m) | (23.2 m) | (71.1 m) | (64.8 m) | (56.9 m) | (82.2 m) |
- Source: SEC Filings
| USD | FY, 2015 | FY, 2016 |
|---|---|---|
Cash | 252.4 m | 187.9 m |
Accounts Receivable | 315 k | 13.3 m |
Inventories | 8.4 m | 26.5 m |
Current Assets | 951.8 m | 772.3 m |
PP&E | 42.1 m | 81.7 m |
Goodwill | 122.1 m | 221.3 m |
Total Assets | 1.4 b | 1.3 b |
Accounts Payable | 4.2 m | 4.4 m |
Current Liabilities | 119.7 m | 114.9 m |
Additional Paid-in Capital | 1.7 b | 1.9 b |
Retained Earnings | (585.7 m) | (831.2 m) |
Total Equity | 1.1 b | 1.1 b |
Financial Leverage | 1.3 x | 1.3 x |
| USD | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|
Cash | 164.2 m | 39.5 m | 569.1 m | 316 m | 285.3 m | 223.4 m | 205.7 m |
Accounts Receivable | 9.3 m | 10.6 m | 8.8 m | ||||
Current Assets | 400.7 m | 307.8 m | 1.2 b | 956 m | 974.6 m | 844.8 m | 779.5 m |
PP&E | 15.4 m | 28.7 m | 36.9 m | 45 m | 51.5 m | 57.7 m | 102.5 m |
Goodwill | 122.1 m | 122.1 m | 221.3 m | 221.3 m | 221.3 m | 221.3 m | |
Total Assets | 476 m | 524.2 m | 1.5 b | 1.5 b | 1.5 b | 1.4 b | 1.3 b |
Accounts Payable | 866 k | 1.9 m | 3 m | 2.2 m | 3.2 m | 3.7 m | 3.2 m |
Current Liabilities | 137.4 m | 160.5 m | 149.4 m | 106.7 m | 143.7 m | 133 m | 122.6 m |
Additional Paid-in Capital | 740.3 m | 789.3 m | 1.6 b | 1.9 b | 1.9 b | 1.9 b | 1.9 b |
Retained Earnings | (411.2 m) | (477.2 m) | (500.4 m) | (656.8 m) | (721.6 m) | (778.5 m) | (913.4 m) |
Total Equity | 329.1 m | 311.3 m | 1.1 b | 1.2 b | 1.2 b | 1.1 b | 1 b |
Financial Leverage | 1.4 x | 1.7 x | 1.3 x | 1.2 x | 1.3 x | 1.3 x | 1.3 x |
| USD | FY, 2015 | FY, 2016 |
|---|---|---|
Net Income | (51.8 m) | (245.6 m) |
Depreciation and Amortization | 2 k | 14.2 m |
Accounts Receivable | 33 k | (13 m) |
Accounts Payable | (2.7 m) | 3.7 m |
Cash From Operating Activities | (103.6 m) | (189.8 m) |
Purchases of PP&E | (42 k) | (56.2 m) |
Cash From Investing Activities | (42 k) | 88.6 m |
Cash From Financing Activities | 66.5 m | 36.8 m |
| USD | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|
Net Income | (65 m) | (66 m) | (23.2 m) | (71.1 m) | (64.8 m) | (56.9 m) | (82.2 m) |
Depreciation and Amortization | 1 m | ||||||
Accounts Receivable | 9.3 m | 10.6 m | 8.8 m | ||||
Accounts Payable | (27 k) | 1.9 m | 3 m | 2.2 m | 3.2 m | 3.7 m | 3.2 m |
Cash From Operating Activities | (21.6 m) | ||||||
Purchases of PP&E | (2.3 m) | ||||||
Cash From Investing Activities | (168.5 m) | ||||||
Cash From Financing Activities | (1.7 m) |
| USD | Y, 2017 |
|---|---|
Revenue/Employee | 35.8 k |
Financial Leverage | 1.3 x |
Juno Therapeutics Operating Metrics
Juno Therapeutics's Patent Applications was reported to be 481 in FY, 2016
- Source: SEC Filings
Juno Therapeutics Market Value History
Market Position of Juno Therapeutics
Traffic Overview of Juno Therapeutics
Juno Therapeutics Online and Social Media Presence
Juno Therapeutics News and Updates
January 26, 2017
Venrock has raised $450 million for its eighth fund — just like its seventh fund
Venrock, the 47-year-old venture firm that started as the venture arm of the Rockefeller family, has closed its eighth fund with $450 million, which longtime partner Bryan Roberts calls “not too big and not too small, but just about right” in a new blog post. Certainly, it’s an amount that the part…
October 27, 2016
Jeff Bezos, Mayo Clinic back anti-aging startup Unity Biotechnology for $116 million
Every once in a while someone in Silicon Valley brings up the possibility of living forever, or at least a really long time, but first we’re going to need to figure out a way to enjoy all those extra years. Unity Biotechnology is a startup focusing on medicines to help us do that by slowing the eff…
July 13, 2016
Study of Juno Therapeutics Leukemia Treatment Is Allowed to Resume
The government said two deaths that prompted it to stop the study had been caused by a drug used in pretreatment, not the leukemia treatment.
July 12, 2016
Shares of Juno Therapeutics jump after FDA removes clinical hold on cancer drug trial
(Reuters) - Juno Therapeutics Inc said U.S. health regulators have removed a clinical hold on its cancer drug trial that was put in place last week following the death of three patients, sending its shares up about 28 percent in extended trading.
July 12, 2016
Study of Juno Therapeutics Cancer Treatment Allowed to Resume
A study of an experimental treatment for leukemia that was halted after two patients died has been allowed to resume after a modification.
July 08, 2016
Pharma Shares Drop After FDA Stops Cancer Therapy Trial for Patient Deaths
Juno Therapeutics was conducting the trial, but other firms also took a hit.